Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Accumulated Expenses (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Other Accumulated Expenses data on record, last reported at $1.8 million in Q2 2025.

  • For Q2 2025, Other Accumulated Expenses rose 66.42% year-over-year to $1.8 million; the TTM value through Jun 2025 reached $1.8 million, up 66.42%, while the annual FY2024 figure was $891000.0, 72.73% down from the prior year.
  • Other Accumulated Expenses reached $1.8 million in Q2 2025 per CRNX's latest filing, up from $1.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.3 million in Q4 2023 and bottomed at $335000.0 in Q4 2022.
  • Average Other Accumulated Expenses over 5 years is $1.1 million, with a median of $912000.0 recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: surged 875.22% in 2023, then crashed 72.73% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $939000.0 in 2021, then tumbled by 64.32% to $335000.0 in 2022, then soared by 875.22% to $3.3 million in 2023, then plummeted by 72.73% to $891000.0 in 2024, then skyrocketed by 101.91% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $1.8 million in Q2 2025, $1.7 million in Q1 2025, and $891000.0 in Q4 2024.